Medetomidine Impurities
General Information
Medetomidine Impurities and Medetomidine
Daicel Pharma offers superior-quality Medetomidine impurities, such as 3-Hydroxy Medetomidine. These impurities are vital for evaluating Medetomidine quality, stability, and biological safety. Further, Daicel Pharma excels in the custom synthesis of Medetomidine impurities and ensures their global delivery.
Medetomidine [CAS: 86347-14-0] is an imidazole derivative. It is used in veterinary medicine. It is helpful as an analgesic in dogs and cats. It is developed by Orion Pharma and approved for use in dogs. Dexmedetomidine is the active d-isomer of Medetomidine.
Medetomidine: Use and Commercial Availability
Medetomidine is a sedative used in veterinary anesthesia. It causes bradycardia for better handling of dogs. Further, it acts as a vasoconstrictor that increases blood pressure and can prevent satisfactory pulse oximetry. It is available as Domitor and is marketed by Pfizer. Its route of administration is either by subcutaneous or intramuscular injection.
Medetomidine Structure and Mechanism of Action
The chemical name of Medetomidine is 5-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole. The chemical formula for Medetomidine is C13H16N2, and its molecular weight is approximately 200.28 g/mol.
Medetomidine stimulates alpha-2 adrenoceptor receptors centrally and causes sedation. It decreases noradrenaline release in the central nervous system, resulting in analgesia.
Medetomidine Impurities and Synthesis
When synthesizing Medetomidine1, the formation of impurities may affect drug safety and efficacy. They form during the manufacturing, storage, or purification of Medetomidine. Medetomidine impurities need constant control and monitoring to ensure that the drug is safe, effective, and stable.
Daicel Pharma offers a comprehensive Certificate of Analysis (CoA) for Medetomidine impurities, which includes 3-Hydroxy Medetomidine. The CoA is from a cGMP-compliant analytical facility and consists of the complete characterization data2, such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity. We give additional spectral data on request. Daicel Pharma can prepare any unidentified Medetomidine impurity or degradation product. In addition, Daicel Pharma offers highly purified, stable isotope-labeled standards of Medetomidine. Clients receive a complete characterization report upon delivery.
References
FAQ's
References
- Karjalainen, Arto Johannes; Pohjala, Esko Kalervo; Kurkela, Kauko Oiva Antero, Substituted imidazole derivatives and their preparation and use, GB2101114B, Jul 10, 1981, Farmos Group, Ltd., Finland (https://www.lens.org/lens/search/patent/list?q=GB2101114)
- Kanazawa, Hideko; Nagata, Yoshiko; Matsushima, Yoshikazu; Takai, Nobuharu; Uchiyama, Hidefumi; Nishimura, Ryohei; Takeuchi, Akira, Liquid chromatography-mass spectrometry for the determination of medetomidine and other anesthetics in plasma, Journal of Chromatography, Volume: 631, Issue: 1-2, Pages: 215-20, 1993 DOI: (10.1016/0021-9673(93)80524-c)
Frequently Asked Questions
Which analytical methods identify and separate Medetomidine impurities in the drug?
Reversed-phase ultra-performance liquid chromatographic (RP-UPLC) can identify and separate Medetomidine impurities in the drug.
Under what conditions does Medetomidine degrade in the drug?
Medetomidine degrades under light and should be stored appropriately.
Why is it necessary to remove Medetomidine impurities from the drug?
Medetomidine impurities can affect drug safety and quality and pose health risks, so it is necessary to remove them from the drug.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.